Clinical trials: Skin Sensitivity
Atopic Dermatitis
Comparison of LimpiAD Cream 2.5% Plus Versus Its Vehicle and and a Basic Emollient in Patients With Atopic Dermatitis
The purpose of this clinical trial is to assess the efficacy and tolerability of LimpiAD, a medical device in the formulation of a 2.5% Plus cream, versus the Vehicle of LimpiAD 2,5% Plus cream, and versus a basic emollient in…
- Trial name
- NCT05984420
- Testing
- LimpiAD 2,5% plus cream, Vehicle, Emollient
- Where
- 5 sites in Italy
- Volunteers
- 200 people
- Sponsor
- Aileens Pharma SRL
Atopic Dermatitis
Study to Evaluate the Use of a Probiotic in SCORAD Reduction in Young Patients With Atopic Dermatitis
The study's objective is to confirm that an oral probiotic treatment reduces the signs and symptoms of moderate atopic dermatitis determined by SCORAD, in patients aged 4 to 17 years, as compared to placebo.
- Trial name
- NCT03822624
- Testing
- Probiotic
- Where
- 3 sites in Spain
- Volunteers
- 70 people
- Sponsor
- Biopolis S.L.
Hemay005, Atopic Dermatitis
A Study of Hemay005 in Adult With Atopic Dermatitis
A multicenter, randomized, double-blind, placebo-controlled, phase II study to evaluate the efficacy and safety of Hemay005 tablet in the treatment of moderate to severe atopic dermatitis.
- Trial name
- NCT05769946
- Testing
- Hemay005
- Where
- China
- Volunteers
- 79 people
- Sponsor
- Ganzhou Hemay Pharmaceutical Co., Ltd
Cryopyrin Associated Periodic Syndrome
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZYIL1 in Subjects With Cryopyrin Associated Periodic Syndromes (CAPS)
ZYIL1 is expected to show benefit in patients with CAPS. The present study aims to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of ZYIL1 when administered to subjects with CAPS.
- Trial name
- NCT05186051
- Testing
- ZYIL1 capsule
- Where
- Australia
- Volunteers
- 3 people
- Sponsor
- Zydus Lifesciences Limited
Breast Cancer
Performance of MammoAlert™, Point of Care System, for the Screening of Breast Cancer in Women 18 Years of Age or Older
POC Medical Systems has developed a Point of Care system for the screening of breast cancer in the general population. Via a proprietary algorithm, the MammoAlert™ is expected to determine breast cancer's risk level for a subject…
- Trial name
- NCT03243877
- Testing
- MammoAlert Screening Test
- Where
- 7 sites in India
- Volunteers
- 2,458 people
- Sponsor
- POC Medical Systems, Inc.
Atopic Dermatitis
A Study of the Long-Term Safety of Crisaborole Ointment, 2% in Japanese Pediatric and Adult Participants With Mild to Moderate Atopic Dermatitis
This study is a Phase 3, multicenter, open-label, long-term safety extension study of Studies C3291032 and C3291031 in Japanese pediatric and adult participants with mild to moderate Atopic Dermatitis (AD).
- Trial name
- NCT04498403
- Testing
- Crisaborole 2%
- Where
- 11 sites in Japan
- Volunteers
- 40 people
- Sponsor
- Pfizer
Atopic Dermatitis
Photocil (Topical) for the Treatment of Atopic Dermatitis
Photocil is a topical drug (cream) that selectively delivers Narrow Band - Ultraviolet B (NB-UVB) therapy when exposed to sunlight.
- Trial name
- NCT01992172
- Testing
- Photocil for Atopic Dermatitis
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Applied Biology, Inc.
Atopic Dermatitis
A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis
This study will assess long-term safety and efficacy of Afimkibart (also known as RO7790121) in participants with Atopic Dermatitis (AD) who participated in previous afimkibart clinical trials.
- Trial name
- Velarite-LTE (NCT07223697)
- Testing
- Afimkibart
- Where
- 31 sites in United States, Brazil and 5 more
- Volunteers
- 120 people
- Sponsor
- Hoffmann-La Roche
Atopic Dermatitis
Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD)
This is an open-label, single-sequence DDI study designed to examine the effects of dupilumab on the pharmacokinetics of selected cytochrome P450 substrates in adult patients with moderate to severe AD.
- Trial name
- NCT02647086
- Testing
- Dupilumab, Midazolam, Omeprazole
- Where
- 5 sites in United States
- Volunteers
- 14 people
- Sponsor
- Regeneron Pharmaceuticals
CVI - Common Variable Immunodeficiency
A Study to Evaluate the Benefit of RUCONEST® in Subjects Who Experience ADRs Related to IVIG Infusions
Patients receiving intravenous immunoglobulin (IVIG) therapy for primary immunodeficiency and neurologic conditions may experience adverse drug reactions (ADRs). The mechanism of the ADR is unknown.
- Trial name
- NCT03576469
- Testing
- C1-esterase inhibitor [recombinant] (C1-INH-R)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- IMMUNOe Research Centers
Atopic Dermatitis
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).
- Trial name
- NCT06947993
- Testing
- GHZ339
- Where
- 105 sites in United States, Argentina and 15 more
- Volunteers
- 224 people
- Sponsor
- Novartis Pharmaceuticals
Dermatitis Atopic
A Study to Assess the Reliability/Feasibility of Using Emerald Touchless Sensor for Scratching and Sleep Quantification in a Subset of Participants From PEDISTAD Study (OBS15333; NCT03687359)
Primary objective: To explore and quantify the association between nighttime scratching and sleep patterns objectively in pediatric participants with moderate to severe atopic dermatitis (AD) using an innovative Emerald touchless…
- Trial name
- NCT05235724
- Where
- 7 sites in United States
- Volunteers
- 18 people
- Sponsor
- Sanofi
Atopic Dermatitis
A First-in-Human Study of CEE321 in Adult Subjects
Open label, non-randomized, uncontrolled, First-in-Human Phase 1 Study in Healthy Subjects and Subjects with Atopic Dermatitis
- Trial name
- NCT04612062
- Testing
- CEE321
- Where
- 3 sites in United States, Japan
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Smallpox, Atopic Dermatitis
Safety Study of MVA Smallpox Vaccine in Subjects With a History of Atopic Dermatitis (AD)
purpose of this study is to assess the safety and immunogenicity of two MVA smallpox vaccine injections in healthy adults that are 18-35 years of age with a history of mild to moderate Atopic Dermatitis.
- Trial name
- NCT00389103
- Testing
- MVA (smallpox vaccine)
- Where
- 3 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dermatitis, Atopic
A Study to Test the Long-term Safety of BI 655130 in Patients With Atopic Eczema Who Took Part in Study 1368-0032
To assess the long term safety and efficacy of treatment with BI 655130 in patients with AD who have completed and have responded to treatment in the parent study 1368-0032
- Trial name
- NCT04086121
- Testing
- Spesolimab
- Where
- 10 sites in United States, Canada and 1 more
- Volunteers
- 14 people
- Sponsor
- Boehringer Ingelheim
Atopic Dermatitis
A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema
The purpose of this study is to find out how well tilrekimig works, how safe it is, and how it affects the body in adults and adolescents with moderate to severe atopic dermatitis (eczema).
- Trial name
- Tilrek (NCT07783425)
- Testing
- Tilrekimig, Dupilumab
- Where
- 32 sites in United States, Japan
- Volunteers
- 1,375 people
- Sponsor
- Pfizer
NALP3 Mutation
Safety, Efficacy, Pharmacokinetics, Pharmacodynamics of ACZ885 in Patients With NALP3 Mutations and Clinical Symptoms
This study will investigate the clinical efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of ACZ885, administered intravenously and subcutaneously to patients with NALP3 mutations whose clinical symptoms are…
- Trial name
- NCT00487708
- Testing
- canakinumab
- Where
- 10 sites in France, Germany and 3 more
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
Allergy to Grass Pollen (Secale Cereale)
Biological Standardization of Secale Cereale Allergen Extract
The objective of this study is to determine the biologic activity of a Secale cereale allergen extract in histamine equivalent prick (HEP) units, in order to be used as in-house reference preparation (IHRP).
- Trial name
- NCT01408238
- Testing
- Four different concentrations of Secale cereale allergen extract, positive control and negative control
- Where
- 2 sites in Spain
- Volunteers
- 35 people
- Sponsor
- Laboratorios Leti, S.L.
Hereditary Angioedema, HAE
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
This study will evaluate the safety and efficacy of an oral treatment, BCX4161, in preventing acute attacks in participants with hereditary angioedema (HAE).
- Trial name
- OPuS-2 (NCT02303626)
- Testing
- BCX4161
- Where
- 40 sites in United States, Belgium and 6 more
- Volunteers
- 110 people
- Sponsor
- BioCryst Pharmaceuticals
Infantile Colic, Constipation
Randomized Placebo-controlled Study of L. Reuteri NCIMB 30351 in GI Functional Disorders and Food Allergy in Newborns
This study is a randomized, placebo-controlled, single-masked (blinded), post-marketing clinical study of a drug Lactobacillus Reuteri NCIMB 30351 drops in functional disorders of gastrointestinal tract and skin symptoms of food…
- Conditions
- Infantile Colic, Constipation, Infantile Diarrhea, Gastro Esophageal Reflux
- Trial name
- NCT04262648
- Testing
- Lactobacillus Reuteri
- Where
- 2 sites in Russia
- Volunteers
- 90 people
- Sponsor
- NovoNatum Ltd